Gynofem Healthcare
As of May 11, 2025, Gynofem Healthcare share price is INR 75.00 per share and the face value is INR 0 per share. The lot size of Gynofem Healthcare is 0 shares. The 52 week high for Gynofem Healthcare is INR 85.00, while the 52 week low is INR 75.00
About Gynofem Healthcare
A Comprehensive Overview of Price & Journey
Understanding Gynofem Healthcare Inception and Growth
SHOW MORE...About Gynofem Healthcare
IPO Details, Price movement
Board of Directors
-
Nishikant Joshi, Director
-
Anurag Mendhe, Director
-
Kartikay Joshi, Director
MISSION STATEMENT
“Gynofem Healthcare Pvt. Ltd. is a company with a mission to build a stronger India in the future. Gynofem focuses on the health of a mother and a nursing mother, so that she remains healthy, gives birth to a healthy child, and hence helps build a stronger nation. Gynofem Healthcare is a company with a mission to combat malnutrition among mothers and children, fight bad health in them, and make them healthy and strong.
Gynofem Healthcare is a company with a mission to take care of the health of every mother and her child, and to keep them healthy.”
VISION STATEMENT
“Gynofem Healthcare Pvt. Ltd.’s vision is to provide innovative, high-technology products that will satisfy the needs of the patients in areas of Gynecology and Obstetrics. Gynofem Healthcare Pvt. Ltd. wishes to emerge as a technology-driven pharmaceutical company offering top-quality and cost-effective healthcare to people of this country.
Gynofem Healthcare is firmly committed to its vision. Technology, research, and Development are the highest priorities of the company. Gynofem policies are market-oriented, keeping in view the benefits of its consumers. Gynofem is committed to promoting class products.”
IPO Details
No information is provided by the company regarding the IPO plans of them. However, the Gynofem share price will likely become a key focus if the company decides to go public in the future, with market trends and investor sentiment influencing its potential valuation.
Dividend Details
No information is provided by the company regarding the Dividend.
Subsidiaries
No information is provided by the company regarding the Subsidiaries of the company.
Industry
The Indian pharmaceutical industry is booming. It jumped from $40 billion in 2021 to an expected $130 billion in 2030, with projections hitting $450 billion by 2047. Beyond just keeping up with the demand at home, the Indian pharma industry commands over 20% of the global pharma supply chain and addresses approximately 60% of the worldwide demand for vaccines.
It meets 40% of the generic demand in the US and provides a quarter of all medicines in the UK. It has undergone a remarkable transformation, evolving into a dynamic powerhouse driving healthcare advancements worldwide. Interestingly, India is the biggest contributor to UNESCO, with a share of over 50-60%. Plus, it boasts the highest number of USFDA-approved plants outside the U.S.
SHOW MORE...Fundamentals
Financials
| P&L Statement | - | - | - | - |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Other Income | - | - | - | - |
| COGS | - | - | - | - |
| Gross Profit | - | - | - | - |
| Total Expense | - | - | - | - |
| EBIDTA | - | - | - | - |
| D&A | - | - | - | - |
| EBIT | - | - | - | - |
| Interest Expense | - | - | - | - |
| PBT | - | - | - | - |
| TAX | - | - | - | - |
| PAT | - | - | - | - |
| Diluted EPS | - | - | - | - |
| Basic EPS | - | - | - | - |
| Total income | 0.00 | 0.00 | 0.00 | 0.00 |
ASSETS
| CURRENT ASSETS | - | - | - | - |
|---|---|---|---|---|
| Cash and Cash Equivalents | - | - | - | - |
| Trade Payables | - | - | - | - |
| Inventory | - | - | - | - |
| Other Current Assets | - | - | - | - |
| Total Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| NON CURRENT ASSETS | - | - | - | - |
|---|---|---|---|---|
| Plant Property and Equipment | - | - | - | - |
| Long Term Investment | - | - | - | - |
| Other Non Current Assets | - | - | - | - |
| TOTOAL NON CURRENT ASSSETS | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Assets | 0.00 | 0.00 | 0.00 | 0.00 |
|---|
| CURRENT LIABILITES | - | - | - | - |
|---|---|---|---|---|
| TRADW Payable | - | - | - | - |
| Other Current Liab | - | - | - | - |
| Total Current Liab | 0.00 | 0.00 | 0.00 | 0.00 |
| NON CURRENTLIABILITIES | - | - | - | - |
|---|---|---|---|---|
| Long Term Debt | - | - | - | - |
| Deffered Tax Liab | - | - | - | - |
| Other Non Current Liab | - | - | - | - |
LIABILITIES
| EQUITY | - | - | - | - |
|---|---|---|---|---|
| Share Capital | - | - | - | - |
| Reserves And Surplus | - | - | - | - |
| Other Equity | - | - | - | - |
| Retained Earnings | - | - | - | - |
| share Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
|---|
| CASH FLOW STAT | - | - | - | - |
|---|---|---|---|---|
| Cash Flow from operating | - | - | - | - |
| Cash Flow from financing | - | - | - | - |
| Cash Flow from investing | - | - | - | - |
| Net cash flow | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue Growth
PAT Growth %
EPS Growth %
TOTAL ASSETS Growth %
QUICK RATIO Growth %
LONG TERM DEBT TO EQUITY RATIO Growth %
Frequently Asked Questions
The lockin period is of 6 months for pre-ipo investors i.e. they cannot sell their shares for 6 months after they get listed. However, they can definitely sell the shares in pre-ipo market before they get listed.